• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Reply: Potential role of Janus kinase inhibitors in COVID-19.

作者信息

Napolitano Maddalena, Fabbrocini Gabriella, Patruno Cataldo

机构信息

Department of Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy.

Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.

出版信息

J Am Acad Dermatol. 2020 Jul;83(1):e65. doi: 10.1016/j.jaad.2020.04.098. Epub 2020 Apr 24.

DOI:10.1016/j.jaad.2020.04.098
PMID:32339701
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7195037/
Abstract
摘要

相似文献

1
Reply: Potential role of Janus kinase inhibitors in COVID-19.回复：Janus激酶抑制剂在2019冠状病毒病中的潜在作用
J Am Acad Dermatol. 2020 Jul;83(1):e65. doi: 10.1016/j.jaad.2020.04.098. Epub 2020 Apr 24.
2
Reply: Calm before the storm: Understanding the role of Janus kinase inhibitors in COVID-19.回复：暴风雨前的平静：了解Janus激酶抑制剂在COVID-19中的作用。
J Am Acad Dermatol. 2020 Jul;83(1):e67-e68. doi: 10.1016/j.jaad.2020.04.097. Epub 2020 Apr 25.
3
Challenges and issues of SARS-CoV-2 pool testing - Authors' reply.严重急性呼吸综合征冠状病毒2型混合检测的挑战与问题——作者回复
Lancet Infect Dis. 2020 Nov;20(11):1234-1235. doi: 10.1016/S1473-3099(20)30455-2. Epub 2020 Jul 14.
4
Loss of Anti-SARS-CoV-2 Antibodies in Mild Covid-19. Reply.轻度新冠肺炎中抗SARS-CoV-2抗体的丧失。回复。
N Engl J Med. 2020 Oct 22;383(17):1697-1698. doi: 10.1056/NEJMc2027051. Epub 2020 Sep 23.
5
Reply to: SARS-CoV-2 as a Potential Trigger of Neurodegenerative Diseases.回复：严重急性呼吸综合征冠状病毒2作为神经退行性疾病的潜在触发因素
Mov Disord. 2020 Jul;35(7):1106-1107. doi: 10.1002/mds.28178.
6
Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation.通过JAK抑制新冠病毒？骨髓增殖性肿瘤（MPN）获批药物鲁索替尼作为治疗SARS-CoV-2诱导的全身炎症反应的潜在策略。
Leukemia. 2020 Jul;34(7):1723-1725. doi: 10.1038/s41375-020-0898-6. Epub 2020 Jun 11.
7
Stability and Viability of SARS-CoV-2. Reply.严重急性呼吸综合征冠状病毒2的稳定性与生存能力。回复。
N Engl J Med. 2020 May 14;382(20):1965-1966. doi: 10.1056/NEJMc2007942. Epub 2020 Apr 13.
8
Asymptomatic coronavirus infection: MERS-CoV and SARS-CoV-2 (COVID-19).无症状冠状病毒感染：中东呼吸综合征冠状病毒和严重急性呼吸综合征冠状病毒2（新型冠状病毒肺炎）
Travel Med Infect Dis. 2020 May-Jun;35:101608. doi: 10.1016/j.tmaid.2020.101608. Epub 2020 Feb 27.
9
Reply to "Does hand hygiene reduce SARS-CoV-2 transmission?".对《手部卫生能减少新冠病毒传播吗？》的回复
Graefes Arch Clin Exp Ophthalmol. 2020 May;258(5):1135. doi: 10.1007/s00417-020-04653-4. Epub 2020 Mar 28.
10
JAK inhibitors in COVID-19: the need for vigilance regarding increased inherent thrombotic risk.JAK 抑制剂在 COVID-19 中的应用：警惕固有血栓形成风险增加的必要性。
Eur Respir J. 2020 Sep 24;56(3). doi: 10.1183/13993003.01919-2020. Print 2020 Sep.

引用本文的文献

1
Cytokine Storm in COVID-19: Insight into Pathological Mechanisms and Therapeutic Benefits of Chinese Herbal Medicines.新型冠状病毒肺炎中的细胞因子风暴：中草药的病理机制及治疗作用洞察
Medicines (Basel). 2024 Jul 18;11(7):14. doi: 10.3390/medicines11070014.
2
Potential treatments of COVID-19: Drug repurposing and therapeutic interventions.COVID-19 的潜在治疗方法：药物再利用和治疗干预。
J Pharmacol Sci. 2023 May;152(1):1-21. doi: 10.1016/j.jphs.2023.02.004. Epub 2023 Feb 15.
3
Identification of novel off targets of baricitinib and tofacitinib by machine learning with a focus on thrombosis and viral infection.通过机器学习识别巴利昔替尼和托法替尼的新脱靶药物，重点关注血栓形成和病毒感染。
Sci Rep. 2022 May 12;12(1):7843. doi: 10.1038/s41598-022-11879-1.
4
JAK out of the Box; The Rationale behind Janus Kinase Inhibitors in the COVID-19 setting, and their potential in obese and diabetic populations.跳出框框看JAK；新冠疫情背景下Janus激酶抑制剂背后的原理及其在肥胖和糖尿病患者群体中的潜力。
Cardiovasc Endocrinol Metab. 2020 Oct 15;10(2):80-88. doi: 10.1097/XCE.0000000000000237. eCollection 2021 Jun.
5
Impact of the COVID-19 pandemic on the course and management of chronic inflammatory immune-mediated skin diseases: What's the evidence?2019年冠状病毒病大流行对慢性炎症性免疫介导性皮肤病病程及管理的影响：有哪些证据？
Clin Dermatol. 2021 Jan-Feb;39(1):52-55. doi: 10.1016/j.clindermatol.2020.12.012. Epub 2020 Dec 15.
6
The interplay between inflammatory pathways and COVID-19: A critical review on pathogenesis and therapeutic options.炎症途径与 COVID-19 的相互作用：发病机制和治疗选择的批判性综述。
Microb Pathog. 2021 Jan;150:104673. doi: 10.1016/j.micpath.2020.104673. Epub 2020 Dec 2.
7
Liver transplant immunosuppression during the covid-19 pandemic.新冠疫情期间的肝移植免疫抑制
Gastroenterol Hepatol. 2020 Oct;43(8):457-463. doi: 10.1016/j.gastrohep.2020.06.003. Epub 2020 Jun 12.
8
Neurological immunotherapy in the era of COVID-19 - looking for consensus in the literature.神经免疫治疗在 COVID-19 时代——在文献中寻找共识。
Nat Rev Neurol. 2020 Sep;16(9):493-505. doi: 10.1038/s41582-020-0385-8. Epub 2020 Jul 8.
9
Cutaneous manifestations and considerations in COVID-19 pandemic: A systematic review.COVID-19 大流行中的皮肤表现和注意事项：系统评价。
Dermatol Ther. 2020 Nov;33(6):e13986. doi: 10.1111/dth.13986. Epub 2020 Aug 6.
10
COVID-19 infection alters kynurenine and fatty acid metabolism, correlating with IL-6 levels and renal status.COVID-19 感染改变犬尿氨酸和脂肪酸代谢，与 IL-6 水平和肾脏状况相关。
JCI Insight. 2020 Jul 23;5(14):140327. doi: 10.1172/jci.insight.140327.

本文引用的文献

1
The use of Janus kinase inhibitors in the time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).在严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫情期间使用Janus激酶抑制剂。
J Am Acad Dermatol. 2020 Jun;82(6):e223-e226. doi: 10.1016/j.jaad.2020.03.099. Epub 2020 Apr 9.
2
Profile of Baricitinib and Its Potential in the Treatment of Moderate to Severe Atopic Dermatitis: A Short Review on the Emerging Clinical Evidence.巴瑞替尼概况及其在中重度特应性皮炎治疗中的潜力：关于新出现临床证据的简短综述
J Asthma Allergy. 2020 Jan 31;13:89-94. doi: 10.2147/JAA.S206387. eCollection 2020.
3
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease.巴瑞替尼作为2019新型冠状病毒急性呼吸道疾病的潜在治疗方法。
Lancet. 2020 Feb 15;395(10223):e30-e31. doi: 10.1016/S0140-6736(20)30304-4. Epub 2020 Feb 4.
4
Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial.乌帕替尼治疗中重度特应性皮炎成人患者：一项随机、安慰剂对照试验的 16 周结果。
J Allergy Clin Immunol. 2020 Mar;145(3):877-884. doi: 10.1016/j.jaci.2019.11.025. Epub 2019 Nov 29.
5
In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494).乌帕替尼（ABT-494）对JAK1选择性的体外和体内特性研究
BMC Rheumatol. 2018 Aug 28;2:23. doi: 10.1186/s41927-018-0031-x. eCollection 2018.
6
Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment.将舒尼替尼和厄洛替尼重新用于登革热治疗的可行性和生物学原理。
Antiviral Res. 2018 Jul;155:67-75. doi: 10.1016/j.antiviral.2018.05.001. Epub 2018 May 16.